Drugs / HZBio1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04765995 | Mar → Oct 2021 | — | Hangzhou Grand Biologic Pharmaceutical, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZBio1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04765995 ↗ |
| Route | Intramuscular | “intramuscularly administered doses of HZBio1” NCT04765995 ↗ |